The potential schematic diagram of selective resident astrocytes elimination attenuated neuropathic pain after SCI.
(A), astrocytes in lumbar enlargement were targeted and selectively eliminated through transgenic mice injected with an adeno-associated virus vector (AAV2/5-GfaABC1D-Cre) and diphtheria toxin. Selective astrocyte elimination in lumbar enlargement could attenuate neuropathic pain after SCI, which were associated with type I IFNs signal and microglia activation. (B), the production of type I IFNs. Type I IFNs production is mainly caused by the contact of innate immune cells (mainly macrophages, microglia and astrocyte in CNS) surface or internal receptors (RIG-I receptor IFIH1/MDA5, cGAS, etc.) with virus specific antigenic substances (DNA, RNA), then through intracellular signal molecule transmission (STING, TBK, IKK, etc.), and finally activate the transcription factor IRF3/7 to promote the expression of type I IFNs, including IFN-α and IFN-β. (C), the signal transduction of type I IFNs. Type I IFNs bind to the same two membrane spanning polypeptide chains type I IFNs receptor 1/2 (IFNAR1/2) (Borden et al., 2007; Owens et al., 2014) and lead to cross phosphorylation and activation of Tyk2/JaK1. Activation of Tyk2 and JAK1 phosphorylate STAT1/2 to form a heterodimer, which then translocate to the nucleus and associate with IRF9 to further form the heterotrimeric transcription factor complex IFN-stimulated gene factor-3 (ISGF3). Finally, ISGF3 translocate to the nucleus and bind to specific IFN-response elements (ISREs) to control the expression of IFNs-stimulated genes (ISGs) (Rothhammer et al., 2016), including ISG15, MX1, OAS1, OAS2, IFIT1, ZBP1.